SCAI2018: New Study Shows 3D Printing Helps Prevent Leaks In Heart-Valve Patients

The clinical use of 3D printing got a boost when interventional cardiologists presented data at the annual meeting of The Society for Cardiovascular Angiography and Interventions that supported th4 technology's effectiveness in helping to predict paravalvular leak in patients undergoing transcatheter aortic valve replacement. The implantation of an ill-fitting valve that can lead to paravalvular leak is a common risk of TAVR procedures.

Two female hands holding a 3d printed human heart

Data from a new study that evaluated the effectiveness of 3D printing and computer modeling in predicting paravalvular leak (PVL) in patients undergoing transcatheter aortic valve replacement (TAVR) has backed the use of the technology for addressing the problem of ill-fitting valves. The data was presented on April 26 at the 41st annual Society for Cardiovascular Angiography and Interventions (SCAI) meeting, which is being held in San Diego through April 28. 

In the study, six patients undergoing TAVR for severe calcific aortic stenosis and at risk for PVL had pre-procedure computed...

More from Cardiology

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the major hurdles in scaling digital innovation, tips for clinical adoption and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMap

In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By 

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By 

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

More from Device Area

Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMap

In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.

GE HealthCare Announces US Launch Of Longer Half-Life PET MPI Agent For Ischemia Detection

 
• By 

GE HealthCare is pursuing a dual-front imaging strategy with its PET MIP agent Flyrcado for detecting artery disease: It lasts longer than current PET scan tracers and allows patients to do treadmill-based stress tests alongside the scan.